interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Abiraterone Acetate; Niraparib Tosylate

Generic competition · all medicines · read 12 November 2026

Is there a generic of Abiraterone Acetate; Niraparib Tosylate, and who makes it?

Abiraterone Acetate; Niraparib Tosylate appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Abiraterone Acetate; Niraparib Tosylate1 dosage-form group in the Orange Book
0generic makers listed
  1. Abiraterone Acetate; Niraparib Tosylate appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Akeega. No generic is listed as marketed.

20202025203020352040204501brand 2023data datePatent 8071579 listed to expire 12 August 2027Patent 8143241 listed to expire 12 August 2027Patent 8436185 listed to expire 24 April 2029Patent 8071623 listed to expire 27 March 2031Patent 8859562 listed to expire 4 August 2031Patent 11986468 listed to expire 28 July 2037Patent 11986469 listed to expire 28 July 2037Patent 11992486 listed to expire 28 July 2037Patent 12383543 listed to expire 28 July 2037Patent 11986470 listed to expire 28 July 2037Patent 11207311 listed to expire 28 July 2037Patent 11673877 listed to expire 27 March 2038Patent 11091459 listed to expire 27 March 2038Patent 12734180 listed to expire 30 September 2043Exclusivity I-980 to 12 December 2028
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 12 December 2028Exclusivity I-980 Akeega
  • 12 August 2027Patent 8071579
  • 12 August 2027Patent 8143241
  • 24 April 2029Patent 8436185 drug substance
  • 27 March 2031Patent 8071623 drug substance
  • 4 August 2031Patent 8859562
  • 28 July 2037Patent 11986468
  • 28 July 2037Patent 11986469
  • 28 July 2037Patent 11992486

6 more patents are listed.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.